Cash, Cash Equivalents and Investments

3 Months Ended

Mar. 31, 2023

Cash, Cash Equivalents and Investments

Cash, Cash Equivalents and Investments

Note 3 - Cash, Cash Equivalents and Investments

The following tables summarize our cash, cash equivalents, marketable securities, and available-for-sale investments at March 31, 2023 and December 31, 2022 (in thousands):

	As of March 31, 2023
			Gross		Gross				Cash and
	Amortized		Unrealized		Unrealized				Cash		Marketable		Short-Term		Long-Term
	Cost		Gains		Losses		Fair Value		Equivalents		Securities		Investments		Investments
Cash	$	213,446	$	—	$	—	$	213,446	$	213,446	$	—	$	—	$	—
Level 1:
Money market funds		49,968		—		—		49,968		49,968		—		—		—
Agency bonds		160,615		39		(230)		160,424		—		—		154,688		5,736
Treasury bills		41,079		6		(2)		41,083		—		—		41,083		—
Marketable securities		90,000		—		(35,190)		54,810		—		54,810		—		—
Subtotal		341,662		45		(35,422)		306,285		49,968		54,810		195,771		5,736
Level 2:
State and municipal obligations		3,026		—		(14)		3,012		—		—		3,012		—
Term deposits		175,000		—		—		175,000		—		—		175,000		—
Corporate bonds		241,401		45		(1,081)		240,365		—		—		226,468		13,897
U.S. government		43,948		—		(158)		43,790		—		—		32,307		11,483
Treasury inflation-protected securities		2,525		17		—		2,542		—		—		2,542		—
Commercial paper		140,029		—		—		140,029		—		—		140,029		—
Subtotal		605,929		62		(1,253)		604,738		—		—		579,358		25,380
Total	$	1,161,037	$	107	$	(36,675)	$	1,124,469	$	263,414	$	54,810	$	775,129	$	31,116

As of March 31, 2023, we had $375.6 million of available-for-sale investments with unrealized losses. Of the $375.6 million of available-for-sale investments with unrealized losses, $17.6 million have been in a continuous unrealized loss position for 12 months or longer, with total gross unrealized losses of $0.6 million. We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases.

During the year ended December 31, 2021, we acquired 9,000,000 shares of common stock of Cellebrite DI Ltd (“CLBT”) with a fair value of $90.0 million. The CLBT common stock is recorded as marketable securities in the accompanying condensed consolidated balance sheets and its fair value is adjusted every reporting period. Changes in fair value are recorded in the condensed consolidated statement of operations as unrealized gain or (loss) on marketable securities, which is included in interest and other income, net. During the three months ended March 31, 2023, we recorded an unrealized gain on marketable securities of $15.6 million relating to CLBT.

	As of December 31, 2022
			Gross		Gross				Cash and
	Amortized		Unrealized		Unrealized				Cash		Marketable		Short-Term		Long-Term
	Cost		Gains		Losses		Fair Value		Equivalents		Securities		Investments		Investments
Cash	$	143,744	$	—	$	—	$	143,744	$	143,744	$	—	$	—	$	—
Level 1:
Money market funds		2,669		—		—		2,669		2,669		—		—		—
Agency bonds		164,486		6		(263)		164,229		—		—		69,862		94,367
Treasury bills		121,650		18		(3)		121,665		113,100		—		8,565		—
Marketable securities		90,000		—		(50,760)		39,240		—		39,240		—		—
Subtotal		378,805		24		(51,026)		327,803		115,769		39,240		78,427		94,367
Level 2:
State and municipal obligations		4,980		—		(33)		4,947		—		—		4,947		—
Certificate of deposits		5,002		—		—		5,002		—		—		5,002		—
Term deposits		200,000		—		—		200,000		25,000		—		175,000		—
Corporate bonds		257,422		33		(1,159)		256,296		28,883		—		168,074		59,339
U.S. Government		30,525		—		(159)		30,366		—		—		30,366		—
Treasury inflation-protected securities		2,503		—		(2)		2,501		—		—		—		2,501
Commercial paper		160,241		—		—		160,241		40,288		—		119,953		—
Subtotal		660,673		33		(1,353)		659,353		94,171		—		503,342		61,840
Total	$	1,183,222	$	57	$	(52,379)	$	1,130,900	$	353,684	$	39,240	$	581,769	$	156,207